Search | OpenScholar

Search results

1935 results found

Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). Parkinsonism Relat Disord 2021;82:133-137.

Publication: Journal Article

Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2021. “Duration of Benefit Per Dose: Carbidopa-Levodopa Immediate Release Vs. Extended Release Capsules (Rytary®). Parkinsonism Relat Disord 2021;82:133-137.”. Parkonsonism Relat Disord.

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.

Publication: Journal Article

Patel, AT, MF Lew, K Dashtipour, S Isaacson, RA Hauser, W Ondo, P Maisonobe, S Wietek, B Rubin, and A Brashear. 2021. “Sustained Functional Benefits After a Single Set of Injections With AbobotulinumtoxinA Using a 2-ML Injection Volume in Adults With Cervical Dystonia: 12-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study.”. ECollection.

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. doi: 10.1155/2021/6638088. eCollection 2021.PMID: 33688424

Publication: Journal Article

Hauser, RA, G Banisadr, K Vuong, D Freilich, S Fisher, and R D’Souza. 2021. “Real-World Experience With Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. Parkinsons Dis. 2021 Feb 19;2021:6638088. Doi: 10.1155/2021/6638088. ECollection 2021.PMID: 33688424”. Parkonsons Dis.

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat Disord 2020;81:144-150.

Publication: Journal Article

Farbman, ES, CH Waters, PA LeWitt, M Rudinska, M Klingler, A Lee, J Qian, C Oh, and RA Hauser. 2020. “A 12-Month, Dose-Level Blinded Safety and Efficacy Study of Levodopa Inhalation Powder (CVT-301, Inbrija) in Patients With Parkinson’s Disease. Parkinsonism Relat Disord 2020;81:144-150.”. Parkinsonism Relat Disord.

Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2020;20:1-10.

Publication: Journal Article

Hauser, RA, JM Meyer, SA Factor, CL Comella, CM Tanner, RM Xavier, SN Caroff, and L Lundt. 2020. “Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. CNS Spectr 2020;20:1-10.”. CNS Spectr.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.

Publication: Journal Article

Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.

Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Mov Disord Clin Pract 2018;5:627-634.

Publication: Journal Article

Hauser, RA, I Biaggioni, LA Hewitt, and S Vernino. 2018. “Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Parkinson Disease. Mov Disord Clin Pract 2018;5:627-634.”. Mov Disord Clin Pract.

NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.

Publication: Journal Article

Hauser, RA, R Li, A Perez, X Ren, D Weintraub, J Elm, JL Goudreau, et al. 2017. “NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure Is Associated With Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.”. J Parkinsons Dis.

Design of a cluster-randomized minority recruitment trial: RECRUIT. Clin Trials 2017;14:286-298.

Publication: Journal Article

Tilley, BC, AG Mainous, DW Smith, MD McKee, RP Amorrortu, J Alvidrez, V Diaz, et al. 2017. “Design of a Cluster-Randomized Minority Recruitment Trial: RECRUIT. Clin Trials 2017;14:286-298.”. Clin Trials.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord 2017;32:1335-1336.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, AP Nicholas, RA Hauser, D Merkitch, and MA Stacy. 2017. “Topiramate As an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. Mov Disord 2017;32:1335-1336.”. Mov Disord.